THE MEMBRANE/AQUEOUS PARTITIONING AS AN ESSENTIAL TOOL FOR PHARMACOKINETIC PROFILING TO SUPPORT DRUG DESIGN

E.Fernandes^{1*}, T.Soares^{1,2}, A.Almeida³, B.Sarmento^{3,4}, M.Elisabete C.D.Real Oliveira¹, M.Lúcio^{1,2}

¹CF-UM-UP, Centro de Física das Universidades do Minho e Porto, Departamento de Física, Universidade do Minho, Braga, Portugal ²CBMA, Centro de Biologia Molecular e Ambiental, Departamento de Biologia, Universidade do Minho, Braga, Portugal ³i3S, Instituto de Investigação e Inovação em Saúde e INEB, Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal ⁴CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra, Portugal

*eduardabfer@gmail.com

INTRODUCTION

- The transport of drugs across cell membranes is a highly complex biological process involving the interaction of drugs with lipid barriers¹. Numerous significant correlations between
- **Lipophilicity** is the net result of all intermolecular when measured forces, and in the liposome/water systems, it also considers the ionic bounds, providing a better correlation with
- Biomembrane mimetic models provide an alternative platform with very well defined and controlled conditions to help researchers from the drug discovery field to predict drugs'

lipophilicity and membrane permeation have been stablished.

the intermolecular forces operating in molecular pharmacology and biochemistry².

pharmacokinetic properties with therapeutic efficacy implications^{3,4}.

Log P_{w/m} in Permeability: ACYCLOVIR

Permeability Coefficient (PC)

Log PC = -5.51 ± 0.04 Log PC = $-6.3 + 0.71 Log P_{w/m} - 0.0061 MW$

Stratum Corneum Content (SCC)

 $Log SCC (per mg) = -3.7 + 7.8Log P_{w/m}$ $Log SCC = 20.09 \pm 0.47$



ACV is a highly lipophilic drug with low

DMPC

Tends to be retained in Stratum Corneum (SC), inhibiting clearance from this compartment



Membrane biphasic systems with **different**

Log P_{w/m} in *off-target* Bioaccumulation: CAMPTOTHECIN



CONCLUSIONS

✓ **Biomembrane Model-Drug** interactions are a promising approach to be adopted for Drug Screening. Providing a solution with more reliable information than octanol/water systems and a better balance of cost:benefit than cell-based assay in such early stage of drug development.

We thank the Fundação para a Ciência e Tecnolgia (FCT) for financial support in the framework of

REFERENCES

1. Lúcio, M., et al.; Curr Med Chem. 2010, DOI: 10.2174/09298671079111233 2. Liu, X., et al., Pharm Res., 2011, DOI: 10.1007/s11095-010-0303-7 3. Fernandes, E.: et al.; Int.J.Mol.Sci. 2018. DOI: 10.3390/ijms19113411 4. Fernandes, E.: et al.; Front. Chem. 2018. DOI: 10.3389/fchem.2018.00323

the Strategic Funding [UID/FIS/04650/2019], and by the project CONCERT [POCI-01-0145-FEDER-032651 and PTDC/NAN-MAT/326512017], co-financed by the European Regional Development Fund (ERDF), through COMPETE 2020, under Portugal 2020, and FCT I.P. We also acknowledge PEst-C/QUI/UI0081/2013, NORTE-01-0145-FEDER-000028 and PTDC/DTP-FTO/2433/2014. E. Fernandes, T. Soares and A. Almeida acknowledges FCT for the PhD grants (SFRH/BD/147938/2019, SFRH/BD/138678/2018 and SFRH/BD/118721/2016, respectively).

AKNOWLEDGEMENTS

 $Log P_{w/m}$

 3.84 ± 0.02

1.0×10-3

5th International Electronic Conference on Medicinal Chemistry 1-30 November 2019

